Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared

Altimmune, Inc.

Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.
No discontinuations due to adverse events; side effects mild-to-moderate, no dose titration needed.
FDA cleared IND for NASH; 12-week NAFLD liver fat trial to start soon.
Phase 2 obesity trial (48-week) planned for H1 2022; diabetes trial expected Q4 2021.
Favorable trends in blood pressure, lipids, HOMA-IR; ketone bodies rise supports glucagon mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.